Yanjun Xu

机构：Changzhi Medical College, Zhejiang Cancer Hospital · ORCID：0000-0001-7187-8804

发表论文 212 篇 · 总被引 4951 次 · h-index 32

代表论文

• Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release (2025 · Journal for ImmunoTherapy of Cancer · 被引 8)
• Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges (2025 · Therapeutic Advances in Medical Oncology · 被引 5)
• Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window (2025 · Cancer Biology and Medicine · 被引 2)
• Clinical Study on Percutaneous Spinal Endoscopic Treatment for New-Onset Lumbosacral Pain Following Vertebral Augmentation Procedures (2025 · World Neurosurgery · 被引 1)
• Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase II studies (2025 · International Journal of Cancer · 被引 1)
• Homeobox C6 plays an oncogenic role in bladder cancer (2025 · World Journal of Clinical Oncology · 被引 1)